Xu, Y., Xu, Y., Tang, M., Li, C., Wu, Y., Dai, Y., Ji, X., Cui, Z., Zhu, X. (2026). Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with
                    <i>RAS</i>
                    -mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3528